Exelixis

YTD

ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,147

Employees1,147

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,147

Employees1,147

EXEL Key Statistics

Market cap

11.57B

Market cap11.57B

Price-Earnings ratio

19.24

Price-Earnings ratio19.24

Dividend yield

—

Dividend yield—

Average volume

5.10M

Average volume5.10M

High today

$43.75

High today$43.75

Low today

$42.26

Low today$42.26

Open price

$43.09

Open price$43.09

Volume

2.89M

Volume2.89M

52 Week high

$48.85

52 Week high$48.85

52 Week low

$20.14

52 Week low$20.14

EXEL News

TipRanks 6d

Promising Outlook for Exelixis: Buy Rating Backed by Zanzalintinib’s Efficacy and Anticipated Phase III Trial Success

William Blair analyst Andy Hsieh has maintained their bullish stance on EXEL stock, giving a Buy rating on May 15. Confident Investing Starts Here: Easily unp...

Analyst ratings

55%

of 20 ratings

Buy

55%

Hold

45%

Sell

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Vertex Pharmaceuticals

United Therapeutics

VeriSign

Sprouts Farmers Market

Gilead Sciences

Novo Nordisk